… In this Review, we discuss the latest developments in local therapy for glioblastoma,
focusing on recent preclinical and clinical trials. The approaches that we discuss include novel …

… Classically, in glioma clinical trials, the most common biomarkers are the status of MGMT …
markers which can predict the treatment response to a particular treatment. This would help …

… Thus, mapping AS is of high clinical importance, to identify novel … To determine the effect
of SRSF5 overexpression (OE), we transfected the patient-derived glioma cell line U87 with …

… associated with satisfactory treatment responses. Therefore, … ), and cortical/subcortical
mapping techniques may be used [… was used in trials in patients with recurrent malignant glioma. …

… immune responses were observed in 93.3% of patients … Patients with immune responses
showed a two-year progression-free rate of 0.82. Two patients without an immune response …

… Researchers are testing the safety/dosing of the NSC-based therapy in combination with
radiation and chemotherapy for patients with newly diagnosed malignant gliomas. The study …

… , therapeutic targets that can contribute to prolonged survival and improved quality of life
for patients with glioblastoma. … from grade I (benign) to grade IV (malignant glioblastoma). …

… , rCBF (e), and APTw (f) maps. Multiparametric MR indices were … of a representative patient
confirmed as treatment effects. Briefly… displays hyperintense in the ADC map. Meanwhile, the …

… determination of treatment responses of malignant brain tumors… the response assessment
of supratentorial malignant gliomas … of BEV (cellularity and cell replication); to identify and map …

… g, Enrichment map network of statistically significant lipid … subtypes and predicted the
therapeutic response of MTC PDCs to … testing the effect of OXPHOS inhibitors in patients with …